Compare IMA & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMA | CING |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.3M | 70.2M |
| IPO Year | 2021 | 2021 |
| Metric | IMA | CING |
|---|---|---|
| Price | $4.11 | $4.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $18.00 | ★ $21.20 |
| AVG Volume (30 Days) | 12.1K | ★ 114.5K |
| Earning Date | 11-20-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.47 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $800,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.88 | $3.16 |
| 52 Week High | $8.84 | $11.89 |
| Indicator | IMA | CING |
|---|---|---|
| Relative Strength Index (RSI) | 42.78 | 36.16 |
| Support Level | $3.91 | $4.19 |
| Resistance Level | $6.13 | $5.31 |
| Average True Range (ATR) | 0.22 | 0.31 |
| MACD | 0.04 | -0.07 |
| Stochastic Oscillator | 39.48 | 3.50 |
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.